Corestem
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Corestem - overview
Established
2003
Location
Seongnam, -, South Korea
Primary Industry
Biotechnology
About
Corestem is a technology company focused on providing innovative solutions that enhance operational efficiency across various sectors, primarily serving clients in North America and Europe. Founded in 2003, Corestem operates out of Seongnam, South Korea. The company has focused on delivering specialized technological solutions and has undergone a significant transition by going public in June 2015. Corestem has completed 2 deals since its inception.
Corestem specializes in delivering innovative solutions tailored to meet specific needs within its target markets. Its primary offerings include a suite of advanced products designed to enhance operational efficiency and drive productivity across various sectors. These products address key challenges faced by businesses, such as streamlining processes and improving data management. The company serves a diverse clientele, including small to medium enterprises, large corporations, and government agencies, establishing a strong customer base primarily in North America and Europe.
In the most recent year, Corestem generated revenue of USD 21. 10 mn with an EBITDA of USD -16. 11 mn. The company follows a structured revenue model encompassing both B2B and direct-to-consumer transactions, where clients typically engage through subscription-based agreements, gaining access to a comprehensive suite of services.
Corestem plans to expand its product line by launching new solutions targeted to enhance operational effectiveness within the next year. The company aims to enter new markets in Asia and Europe by the end of 2025. The funding secured from its public offering will support these initiatives, providing the necessary capital for research and development as well as market entry strategies.
Current Investors
SL Investment
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Healthcare
Website
www.corestem.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Corestem - timeline of key events
Corestem - financials
| Fiscal Year Ended | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 3,654,519,519 | 12,987,984,497 | 18,571,078,685 | 17,953,023,532 | 18,094,301,462 | 22,316,891,009 | 24,284,457,085 | 26,357,703,198 | 30,240,039,388 | 46,293,144,603 | - | - | - |
| % Revenue Growth (YoY) | - | 255.4% | 43.0% | (3.3%) | 0.8% | 23.3% | 8.8% | 8.5% | 14.7% | 53.1% | - | - | - |
| EBITDA (USD) | (2,048,881,766) | (871,338,823) | 2,439,954,710 | (444,698,568) | (3,564,316,769) | (1,943,027,908) | (1,961,642,237) | (3,490,876,905) | (6,663,932,047) | (1,413,263,167) | - | - | - |
| Operating Income (USD) | (2,405,752,766) | (1,803,570,823) | 1,367,663,710 | (1,623,643,568) | (5,070,659,769) | (4,020,567,908) | (5,088,389,237) | (6,998,079,905) | (10,549,814,047) | (6,013,330,167) | - | - | - |
| Operating Margin | (65.8%) | (13.9%) | 7.4% | (9.0%) | (28.0%) | (18.0%) | (21.0%) | (26.6%) | (34.9%) | (13.0%) | - | - | - |
| % EBITDA Margin | (56.1%) | (6.7%) | 13.1% | (2.5%) | (19.7%) | (8.7%) | (8.1%) | (13.2%) | (22.0%) | (3.1%) | - | - | - |
| NET Income (USD) | (3,432,032,779) | (6,325,458,076) | 277,295,194 | (1,218,280,597) | (4,754,604,133) | (3,082,155,249) | (4,370,276,106) | (22,384,006,221) | (4,996,381,858) | 1,000,908,061 | - | - | - |
| % Net Margin | (93.9%) | (48.7%) | 1.5% | (6.8%) | (26.3%) | (13.8%) | (18.0%) | (84.9%) | (16.5%) | 2.2% | - | - | - |
Corestem - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IPO | Completed | Corestem | - | ||||||||
| Buyout | Completed | Corestem | - |
Displaying 1 - 2 of 2
Corestem - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.